Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants

• Status: Completed
• Trial end date: 2004-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if kidney function can be improved during transplants by giving the drug Thymoglobulin with delayed cyclosporine treatment instead of initial cyclosporine treatment.

There have been improvements for patients receiving kidney transplants, yet acute rejection is still a problem. This can lead to kidney failure over time. Patients whose graft fails to function properly in the first week after transplant do not do as well after 5 years as compared to patients without early problems. This study will see if Thymoglobulin, a drug that suppresses the immune system, will improve early graft function.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Antibodies; Cyclosporine; Cyclosporins; Immunoglobulins; Tacrolimus; Thymoglobulin

Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

• Are receiving a first or second kidney transplant.

• Are at least 21 years old.

• Understand the purposes and risks of the study and have given consent.

• Agree to use an acceptable form of birth control for a year following transplant.

Exclusion Criteria

Patients will not be eligible for this study if they:

• Have received a kidney transplant from a living donor.

• Have had multiple organ transplants.

• Are allergic to Thymoglobulin (contains a rabbit protein).

• Are pregnant.